Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)

Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)

<p>Abstract</p> <p>Background</p> <p>Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this study were to (i) formally evaluate systolic and diastolic blood pressure reduction as a surrogate endpoint for stroke prevention an...

Full description

Bibliographic Details
Main Authors: Lassere Marissa N, Johnson Kent R, Schiff Michal, Rees David
Format: Article
Language:English
Published: BMC 2012-03-01
Series:BMC Medical Research Methodology
Subjects:
Blood pressure
Stroke
Surrogate Endpoint
Biomarker
Online Access:http://www.biomedcentral.com/1471-2288/12/27

Internet

http://www.biomedcentral.com/1471-2288/12/27

Similar Items